PHARMA MAR, S.A. The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 21/03/2018 19:24 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 260272 the EMA has advanced to Pharma Mar that the CHMP confirms its negative Opinion issued in December 2017 in relation to Aplidin in the multiple myeloma indication. Register number: 263165
